|Bid||23.30 x 1200|
|Ask||26.08 x 800|
|Day's Range||24.79 - 25.48|
|52 Week Range||17.80 - 33.54|
|Beta (3Y Monthly)||2.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Some of the biggest names in gene editing are on Colorado's Front Range, and they're looking to transform how disease is treated.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
CRISPR is a gene-editing technique that enables the targeting and editing of specific sequences in the human DNA. It has been around for a couple of years, and recently, researchers in the U.S. have started using it to alter the genes of adults suffering from progressive disorders and diseases. The scientific community largely shunned the experiment, as CRISPR is known to result in unwanted gene edits, which, in the case of embryos (as well as sperm and eggs), are carried over to their offspring.
The German-based drug giant has doubled down on one of its previous investments, announcing a deal to acquire the remainder of the stake in BlueRock Therapeutics for $600 million.
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
The legal battle over a method of altering a person’s genes that’s worth billions of dollars escalated this week, with the University of California alleging that the Cambridge-based Broad Institute withheld information in an attempt to deceive U.S. patent officials.
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.